COVID-19对大脑的急性和长期影响的分子影像学表现:一项系统综述
该系统综述总结了PET和SPECT等分子影像技术用于揭示COVID-19如何影响人脑的现有文献,按五个主要主题归纳:罕见的脑炎相关可逆性代谢改变、帕金森综合征样表现、局灶症状(如嗅觉减退)相关区域代谢改变、COVID-19相关脑病住院患者的额顶叶主导新皮质功能障碍(多数6个月内大致可逆)、以及post-COVID-19综合征的矛盾结果。作者还对研究方法学问题和当前病理生理学概念进行了批判性评价,并提出了PET和SPECT在COVID-19相关诊断问题临床检查中的可能应用。
要点
- COVID-19相关脑病住院患者急性至亚急性期可见额顶叶主导的新皮质功能障碍,影像和临床均显示,多数病例至6个月时大致可逆。
- 少数伴发感染期或感染后脑炎的罕见病例中,已有病例报告提示可逆的皮质和皮质下代谢改变。
- post-COVID-19综合征的研究结果存在争议:部分作者发现边缘系统和皮质下广泛代谢减低,另一些作者未发现PET代谢改变。
核心结论
- 分子影像学在COVID-19脑部受累的不同临床情境中显示多样表现,但现有数据有限且方法学问题常见,部分领域结论尚不一致。
- 作者提出了PET和SPECT在COVID-19相关诊断问题临床检查中的可能应用。
研究设计与样本
- 系统综述,按5个主要主题总结当前文献,并对研究方法学问题和当前病理生理学概念进行批判性评价。
主要发现
- 少数伴发感染期或感染后脑炎的罕见病例报告中,提示可逆的皮质和皮质下代谢改变。
- 在COVID-19背景下首次出现帕金森综合征表现的单个患者中,影像学表现类似神经变性性帕金森综合征(黑质纹状体完整性丧失),但数据稀少且缺乏随访,无法进一步得出病因学结论。
- 关于局灶症状和病灶(最显著为嗅觉减退)的病例报告和小型系统研究结果不一,部分研究发现与嗅觉相关区域(如眶额叶和内侧颞叶)的局部代谢减低。
- COVID-19相关脑病住院患者(急性至亚急性期)的病例系列和系统研究一致发现额顶叶主导的新皮质功能障碍(影像学和临床上),多数病例至6个月时大致可逆。
- post-COVID-19综合征研究中,在自我报告症状(如疲劳、记忆障碍、嗅觉减退和呼吸困难)负担高的患者中,部分作者发现边缘系统和皮质下广泛代谢减低区域,而另一些作者在PET上未发现代谢改变,神经心理学评估仅见轻微认知障碍(如有)。
临床怎么用
- 作者提出了PET和SPECT在COVID-19相关诊断问题临床检查中的可能应用。
局限性
- 在COVID-19背景下首次出现帕金森综合征表现的患者中,数据稀少且缺乏随访,无法进一步得出病因学结论。
- post-COVID-19综合征的研究结果存在争议。
- 作者对研究方法学问题进行了批判性评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular imaging techniques such as PET and SPECT have been used to shed light on how coronavirus disease 2019 (COVID-19) affects the human brain. We provide a systematic review that summarizes the current literature according to 5 predominant topics. First, a few case reports have suggested reversible cortical and subcortical metabolic alterations in rare cases with concomitant para- or postinfectious encephalitis. Second, imaging findings in single patients with the first manifestations of parkinsonism in the context of COVID-19 resemble those in neurodegenerative parkinsonism (loss of nigrostriatal integrity), but scarceness of data and a lack of follow-up preclude further etiologic conclusions (e.g., unmasking/hastening of neurodegeneration vs. infectious or parainfectious parkinsonism). Third, several case reports and a few systematic studies have addressed focal symptoms and lesions, most notably hyposmia. The results have been variable, although some studies found regional hypometabolism of regions related to olfaction (e.g., orbitofrontal and mesiotemporal). Fourth, a case series and systematic studies in inpatients with COVID-19-related encephalopathy (acute to subacute stage) consistently found a frontoparietal-dominant neocortical dysfunction (on imaging and clinically) that proved to be grossly reversible in most cases until 6 mo. Fifth, studies on post-COVID-19 syndrome have provided controversial results. In patients with a high level of self-reported complaints (e.g., fatigue, memory impairment, hyposmia, and dyspnea), some authors found extensive areas of limbic and subcortical hypometabolism, whereas others found no metabolic alterations on PET and only minor cognitive impairments (if any) on neuropsychologic assessment. Furthermore, we provide a critical appraisal of studies with regard to frequent methodologic issues and current pathophysiologic concepts. Finally, we devised possible applications of PET and SPECT in the clinical work-up of diagnostic questions related to COVID-19.
引用
- Meyer PT, Hellwig S, Blazhenets G, et al. Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review. J Nucl Med. 2022. PMID: 35177424. doi:10.2967/jnumed.121.263085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。